BPC-2 is under clinical development by Meabco and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BPC-2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BPC-2 overview
BPC-2 is under development for the prevention and treatment of side effects from radiation exposure and chemotherapy. The therapeutic candidate is formulated as solution and administered orally. BP-C2 is a lignin-derived polyphenolic composition with ammonium molybdate. BP-Cx-1, a globular polydentant ligand, is a refined humic substance consisting of acid polymers of the benzo-poly-carbonic family. The drug candidate is developed based on the polyphenolic technology platform.
BPC-2 was under development for the treatment of prostate cancer.
Meabco overview
Meabco is a biotechnology company. It develops cancer therapy products. The company focuses on various therapeutic cancer challenges areas including pancreatic cancer, metastatic breast cancer and prostate cancer. It develops anticancer drugs that include BP-C1 and BP-C2 that mitigate radiation and chemotherapy damages. Meabco’s BP-C2 drug candidate improves the hematopoietic system and protects the gastrointestinal system and helps in their recovery following damage induced by radiation, disease and chemical agents. It collaborates with institutions and scientists to enhance its research and development. The company operates in Denmark and the US. Meabco is headquartered in Copenhagen, Denmark.
For a complete picture of BPC-2’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
